Targeting a newly-discovered adhesion checkpoint

The PointGuard first-in-man clinical trial is expected to provide valuable efficacy & mechanistic biomarkers data. It is a randomized, blinded, placebo-controlled dose-ranging study evaluating the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of subcutaneous single and multiple ascending doses o